Trends in Survival Based on Treatment Modality in Non-Small Cell Lung Cancer Patients: A Population-Based Study

Akhtar–Danesh, Noori; Akhtar-Danseh, Gileh-Gol; Seow, Hsien; Shakeel, Saad; Finley, Christian

doi:10.1080/07357907.2019.1653465

Cited by 6 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…29,30 For both lung and colorectal cancers, improvements in diagnostic pathways and clinical management have led to reductions in mortality, with improved survival reported for most stages at diagnosis. 20,[31][32][33] In our analyses, we highlighted several other cancers (i.e., liver and intrahepatic bile duct cancer, kidney cancer, melanoma and head and neck cancers) with concerning trends. Over the past 4 decades, some of the fastest increases in cancer rates in Canada were seen for these cancers.…”

Section: Discussionmentioning

confidence: 87%

See 1 more Smart Citation

Projected estimates of cancer in Canada in 2024

Brenner,

Gillis,

Demers

et al. 2024

CMAJ

Self Cite

View full text Add to dashboard Cite

Background: Cancer surveillance data are essential to help understand where gaps exist and progress is being made in cancer control. We sought to summarize the expected impact of cancer in Canada in 2024, with projections of new cancer cases and deaths from cancer by sex and province or territory for all ages combined. Methods: We obtained data on new cancer cases (i.e., incidence, 1984–2019) and deaths from cancer (i.e., mortality, 1984–2020) from the Canadian Cancer Registry and Canadian Vital Statistics Death Database, respectively. We projected cancer incidence and mortality counts and rates to 2024 for 23 types of cancer, overall, by sex, and by province or territory. We calculated age-standardized rates using data from the 2011 Canadian standard population. Results: In 2024, the number of new cancer cases and deaths from cancer are expected to reach 247 100 and 88 100, respectively. The age-standardized incidence rate (ASIR) and mortality rate (ASMR) are projected to decrease slightly from previous years for both males and females, with higher rates among males (ASIR 562.2 per 100 000 and ASMR 209.6 per 100 000 among males; ASIR 495.9 per 100 000 and ASMR 152.8 per 100 000 among females). The ASIRs and ASMRs of several common cancers are projected to continue to decrease (i.e., lung, colorectal, and prostate cancer), while those of several others are projected to increase (i.e., liver and intrahepatic bile duct cancer, kidney cancer, melanoma, and non-Hodgkin lymphoma). Interpretation: Although the overall incidence of cancer and associated mortality are declining, new cases and deaths in Canada are expected to increase in 2024, largely because of the growing and aging population. Efforts in prevention, screening, and treatment have reduced the impact of some cancers, but these short-term projections highlight the potential effect of cancer on people and health care systems in Canada.

show abstract

Section: Discussionmentioning

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Projected estimates of cancer in Canada in 2024

Brenner,

Gillis,

Demers

et al. 2024

CMAJ

Self Cite

View full text Add to dashboard Cite

show abstract

“…Pour l’incidence du cancer colorectal, des programmes de dépistage organisés ont mené à des réductions importantes des TINA ces dernières années 29 , 30 . Pour les cancers du poumon et le cancer colorectal, des améliorations aux voies de dépistage et à la prise en charge clinique ont mené à des réductions de la mortalité, avec des taux de survie améliorés pour la plupart des stades de diagnostic 20 , 31 – 33 .…”

Section: Interprétationunclassified

Projection du fardeau du cancer au Canada en 2024

Brenner,

Gillis,

Demers

et al. 2024

CMAJ

View full text Add to dashboard Cite

“…Over the past 20 years, various treatments including chemotherapy, targeted therapy, and immunotherapy have proven effective for some advanced NSCLC patients [5]. However, the overall survival (OS) and cure rates of NSCLC remain Ivyspring International Publisher low, with a 5-year survival rate of between 2% and 13% in patients with metastatic disease [6]. Therefore, exploring the in-depth molecular mechanisms of NSCLC development to identify potential targets for novel therapeutic strategies to improve survival is urgently needed.…”

Section: Introductionmentioning

confidence: 99%

PLEKHG2 Promotes NSCLC Cell Growth by Increasing Glycolysis via Activated PI3K/AKT Pathway

Xia,

Feng,

Ning

et al. 2023

J. Cancer

View full text Add to dashboard Cite

Purpose: PLEKHG2 is a member of the diffuse B-cell lymphoma family. The function of PLEKHG2 in NSCLC was still unclear. This study aimed to investigate the relationship between the upregulated expression of PLEKHG2 and the prognosis of NSCLC and to revealed its mechanisms. Materials and methods:The expression of PLEKHG2 in NSCLC patients and its relationship with prognosis were first determined by analyzing public databases. Validation was performed in NSCLC cell lines and patient`s tumor tissues. PLEKHG2-silenced H1299 cells and PLEKHG2 overexpressing PC9 cells were constructed and used to validate its function. Glycolysis was evaluated by assaying cellular metabolites, glucose uptake and the expression levels of biomarkers of glycolysis. The relationship of PLEKHG2 and the PI3K/Akt pathway was demonstrated by small molecule inhibitors. The function of PLEKHG2 was evaluated in vivo by a H1299 cell derived xenograft (CDX) model. Results: PLEKEHG2 was highly expressed in NSCLC tissues and associated with poor prognosis. In PLEKHG2 knockdown H1299 cells, ATP and lactate production and glucose uptake were significantly inhibited. The opposite results were observed in PC9 cells with PLEKHG2 overexpression. The increased glycolysis following PLEKHG2 overexpression was abolished by adding the PI3K/AKT pathway inhibitor LY294002, suggesting that PLEKHG2 promotes glycolysis in NSCLC cells via activation of the PI3K/AKT pathway. Finally, we found that PLEKHG2 knockdown inhibited the tumor growth in the H1299 CDX model. Conclusion: PLEKHG2 contributed to NSCLC development by promoting glycolysis via activation of the PI3K/AKT pathway. PLEKHG2 was a potential therapeutic target and biomarker for poor prognosis of NSCLC.

show abstract

Trends in Survival Based on Treatment Modality in Non-Small Cell Lung Cancer Patients: A Population-Based Study

Cited by 6 publications

References 31 publications

Projected estimates of cancer in Canada in 2024

Projected estimates of cancer in Canada in 2024

Projection du fardeau du cancer au Canada en 2024

PLEKHG2 Promotes NSCLC Cell Growth by Increasing Glycolysis via Activated PI3K/AKT Pathway

Contact Info

Product

Resources

About